Cellebrite (CLBT) Form 144 Filed for 40,535-Share Sale on NASDAQ
Rhea-AI Filing Summary
Form 144 filing for Cellebrite DI Ltd. (CLBT) reports a proposed sale of 40,535 common shares held as restricted stock units acquired on 02/15/2023. The filing lists Morgan Stanley Smith Barney LLC as the broker and an approximate aggregate market value of $728,413.95 with an expected sale date of 09/23/2025 on NASDAQ. The filer represents they are unaware of any undisclosed material adverse information. The filing also discloses 10b5-1 sales executed on 09/22/2025 totaling 25,810 shares for gross proceeds of $464,610.97. The issuer’s total shares outstanding are stated as 244,469,106.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider plans to sell a modest block of restricted stock units; prior 10b5-1 sales also disclosed.
The filing documents a proposed sale of 40,535 common shares acquired as restricted stock units and scheduled with Morgan Stanley Smith Barney. The disclosed aggregate market value is $728,413.95 against an outstanding share base of 244,469,106, indicating the position is small relative to total capitalization. The filing also confirms a 10b5-1 sale of 25,810 shares on 09/22/2025 for $464,610.97. The signer attests no undisclosed material adverse information. For investors, this is a routine insider liquidity event rather than a corporate action.
TL;DR: Disclosure meets Rule 144 and 10b5-1 notice requirements; no governance red flags in the text provided.
The document provides required details: acquisition date (02/15/2023), nature of acquisition (Restricted Stock Units), broker details, intended sale date (09/23/2025), and prior 10b5-1 sales. The signer’s representation about lacking material nonpublic information is included, as expected. There are no statements here about executive departures, related-party transactions, or regulatory issues. As presented, the filing appears procedural and compliant with disclosure norms.
FAQ
What does the Form 144 filed for CLBT disclose?
Were any recent insider sales reported for CLBT?
How many CLBT shares are outstanding per the filing?
What type of acquisition created the shares being sold?
Which broker is handling the proposed CLBT sale?